List of Excipients in Branded Drug TOTECT

« Back to Dashboard

Totect Excipient Strategy and Commercial Opportunities in Dexrazoxane Injection

Last updated: September 24, 2026

Totect is an intravenous dexrazoxane hydrochloride product approved in the United States to reduce the incidence and severity of anthracycline extravasation injury. Its commercial value is driven less by a differentiated excipient system than by emergency-use logistics, rapid preparation, hospital availability, and reliable three-day dosing. The strongest formulation opportunities are ready-to-use presentation, reduced reconstitution burden, improved in-use stability, and differentiated hospital supply models.

What is Totect and how is it administered?

Totect contains dexrazoxane hydrochloride for intravenous infusion. It is indicated for extravasation resulting from intravenous anthracycline chemotherapy, including doxorubicin and epirubicin, and must be initiated within six hours of the extravasation event.[1]

The labeled regimen is:

Treatment day	Dose
Day 1	1,000 mg/m²
Day 2	1,000 mg/m²
Day 3	500 mg/m²

The dose is administered as an intravenous infusion over one to two hours. Treatment is generally not recommended for patients with severe renal impairment, and dosing requires adjustment for patients with creatinine clearance below 40 mL/min.[1]

Totect is supplied as a sterile powder for reconstitution. The hospital must reconstitute the vial with Sterile Water for Injection and then dilute the resulting solution in a compatible intravenous fluid before administration. The product is therefore a preparation-dependent emergency therapy rather than a conventional pharmacy-dispensed injection.

What excipients are used in Totect?

Totect’s primary formulation characteristic is the absence of a complex excipient platform. The commercial presentation is a lyophilized dexrazoxane hydrochloride powder for reconstitution. The labeled preparation process uses:

• Dexrazoxane hydrochloride as the active pharmaceutical ingredient
• Sterile Water for Injection for reconstitution
• Sodium chloride injection or another label-authorized compatible infusion solution for final dilution

The product is not positioned around a lipid vehicle, surfactant system, preservative, cosolvent, or sustained-release excipient. The formulation strategy prioritizes chemical stability, sterility, rapid dissolution, and compatibility with hospital infusion systems.[1]

Excipient-related formulation requirements

A follow-on or reformulated dexrazoxane product would need to manage several technical requirements:

Formulation issue	Commercial relevance
Rapid dissolution	Reduces treatment delay after an extravasation event
Low particulate burden	Supports intravenous administration and hospital pharmacy acceptance
pH control	Affects solubility, tolerability, and container compatibility
Reconstitution volume	Determines pharmacy labor and preparation time
Diluent compatibility	Reduces risk of precipitation or adsorption
In-use stability	Supports batch preparation and emergency stock management
Container closure integrity	Important for sterile powder storage and transport
Low endotoxin burden	Required for injectable use
Cold-chain or room-temperature stability	Affects hospital inventory and distribution economics

The lack of a complex excipient system reduces formulation barriers but also limits composition-based differentiation. Commercial protection is more likely to come from presentation, device integration, stability, manufacturing process, or regulatory positioning.

What formulation patents could protect a Totect follow-on product?

A dexrazoxane follow-on product could pursue protection in four technical areas.

Ready-to-use or low-preparation presentations

A premixed dexrazoxane infusion could reduce the number of pharmacy steps required during an emergency. Potential claims could cover:

• A stable aqueous dexrazoxane solution
• A specified concentration range
• A defined pH window
• A specified storage temperature and shelf life
• A container made from a compatible polymer or glass
• A bag, syringe, or vial presentation suitable for direct infusion

This route has the greatest practical value but also the highest chemical-stability risk. A ready-to-use product must address degradation, oxidation, container interaction, microbial control, and shelf life.

Dual-chamber or integrated reconstitution systems

A dual-chamber vial, dual-compartment syringe, or connected transfer device could separate the dexrazoxane powder from the reconstitution fluid until use. Claims could focus on:

• The chamber arrangement
• The transfer pathway
• Automatic mixing
• Closed-system transfer
• Reduced operator exposure
• Time-to-reconstitution
• Final concentration control

This strategy could offer stronger device and process differentiation than a conventional excipient change.

Stabilized liquid formulations

A liquid formulation might use a pH-adjusting system, antioxidant, chelator, or other stabilizing excipient. Any such approach would require a clear benefit over the current powder presentation. Potential benefits include:

• Longer room-temperature stability
• Reduced degradation after dilution
• Lower particulate formation
• Greater compatibility with infusion bags
• Extended in-use storage

The main regulatory risk is that a new excipient or changed excipient level can move the product outside a straightforward ANDA pathway, particularly if the change affects pharmacokinetics, local tolerability, or product performance.

Improved lyophilized formulations

A modified freeze-dried cake could improve dissolution without introducing a complex excipient system. Patentable features could include:

• Specific lyophilization cycle parameters
• Residual moisture limits
• Cake structure
• Reconstitution time
• Stability after manufacture
• Container closure and headspace controls

This approach is less commercially visible than a premixed product but may offer a lower development risk than an aqueous formulation.

What is the regulatory pathway for a dexrazoxane formulation change?

A product with the same active ingredient, dosage form, route, strength, and comparable inactive ingredients could potentially use the abbreviated new drug application pathway. A formulation with a new excipient, a different concentration, a new delivery system, or a new stability profile may require a 505(b)(2) application or another FDA-supported pathway.[2]

The regulatory positioning depends on the extent of the change:

Product concept	Likely regulatory issue
Same powder, same strength, same reconstitution method	Potential ANDA opportunity
Same powder with different vial or closure	CMC and equivalence assessment
New excipient level	Inactive-ingredient and safety justification
Ready-to-use liquid	Stability, sterility, degradation, and equivalence
Prefilled syringe	Device combination-product requirements
Dual-chamber presentation	Device, human-factors, and CMC requirements
New indication	Clinical and labeling requirements
New dosing regimen	Clinical justification and possible 505(b)(2) requirements

For an emergency extravasation therapy, FDA and hospital buyers will place substantial weight on preparation reliability. A product that requires less manipulation may have a commercial advantage even if the active ingredient and clinical use remain unchanged.

When does Totect lose exclusivity and what is its Orange Book status?

Totect was approved by FDA in 2007 under NDA 022268 for dexrazoxane hydrochloride for injection.[1] Any standard regulatory exclusivity associated with that approval has expired. The commercial assessment should therefore focus on active patents, Orange Book-listed patents, manufacturing know-how, supply continuity, and hospital contracting rather than on original approval exclusivity.

The FDA Orange Book is the relevant source for identifying patents and exclusivity listed against a specific NDA.[3] A formulation developer should distinguish between:

• Patents listed against Totect
• Patents covering dexrazoxane generally
• Patents covering a separate dexrazoxane product or indication
• Unlisted formulation, process, device, or manufacturing patents
• Regulatory exclusivity that has already expired

Because Totect uses an older active pharmaceutical ingredient and a conventional sterile-powder presentation, the most meaningful intellectual-property opportunities are likely to involve formulation details, device architecture, stability, manufacturing process, and packaging rather than broad composition-of-matter protection.

Are Paragraph IV challenges and generic entry risks material?

The primary generic risk is substitution through an ANDA for a conventional dexrazoxane hydrochloride injectable product. A generic competitor could target the same active ingredient, strength, route, and dosage form while competing on price, supply reliability, or hospital purchasing contracts.

Paragraph IV litigation risk would depend on whether any enforceable Orange Book-listed patents remain associated with Totect. The commercial risk is higher if a listed patent covers the basic injectable presentation or a clinically important preparation method. It is lower if only narrow formulation or device patents remain.

Generic entry would likely occur in several scenarios:

1. A conventional lyophilized vial with comparable reconstitution instructions.
2. A lower-cost product marketed to oncology hospitals and outpatient infusion centers.
3. A contract-manufactured product supplied through group purchasing organizations.
4. A product with improved vial count or packaging economics.
5. A product bundled with extravasation kits or oncology emergency products.

The absence of a complex excipient system makes design-around comparatively feasible. A competitor may avoid narrow formulation claims by using a different lyophilization process, vial configuration, or reconstitution volume.

What commercial opportunities exist for Totect excipient innovation?

Ready-to-use emergency infusion

A ready-to-use product could command a premium if it reduces preparation time and decreases medication-error risk. The target customers would include:

• Comprehensive cancer centers
• Community oncology practices
• Emergency departments
• Hospital pharmacies
• Ambulatory infusion centers
• Specialty distributors

The commercial case depends on maintaining adequate shelf life without requiring burdensome refrigeration or complex handling.

Lower-vial-count packaging

The three-day dosing regimen can create substantial inventory and preparation requirements. Packaging could be optimized around common adult body-surface-area doses, although fixed-dose packaging must preserve dosing flexibility.

Commercial options include:

• Three-day treatment kits
• Hospital emergency stock kits
• Unit-dose cartons
• Bundles containing reconstitution supplies
• Barcode-enabled pharmacy packs
• Small-volume emergency inventory configurations

A bundled kit may create value without changing the drug formulation. The opportunity is operational efficiency rather than pharmacological differentiation.

Closed-system transfer and pharmacy safety

A connected reconstitution device could reduce needle manipulation and simplify preparation. The value proposition is strongest in hospitals with centralized oncology pharmacies and strict hazardous-drug handling procedures.

Dexrazoxane itself is not the anthracycline cytotoxic drug causing the extravasation injury, but it is used in a high-risk oncology workflow. A product that reduces preparation steps can be differentiated through device performance and pharmacy safety.

Stable diluted solution

If technically achievable, extended in-use stability could allow hospitals to prepare doses before administration and reduce waste. The product would need validated stability after:

• Reconstitution
• Transfer to the infusion bag
• Refrigerated storage
• Room-temperature storage
• Exposure to light
• Connection to common administration sets

This is a technically attractive opportunity but requires robust analytical and microbiological data.

How strong is the Totect patent estate?

The apparent patent strength is moderate to weak for broad excipient protection and potentially stronger for narrow presentation or process claims.

Patent category	Expected strategic strength
Dexrazoxane composition of matter	Low for new-product exclusivity
Conventional lyophilized vial	Low to moderate
Novel liquid formulation	Moderate if stability is demonstrated
Dual-chamber delivery system	Moderate to strong
Closed-system transfer device	Moderate
Manufacturing process	Moderate if difficult to reproduce
Packaging and emergency kit	Low to moderate
Method of treating anthracycline extravasation	Potentially relevant but generally narrow
New indication	Dependent on clinical and regulatory support

A strong product strategy would combine a formulation patent with device claims, manufacturing claims, and trade secrets covering scale-up and stability. A single excipient claim is unlikely to provide durable commercial protection unless it delivers a material stability or administration benefit.

How does Totect compare with competing dexrazoxane products?

Attribute	Totect	Zinecard and related dexrazoxane products
Active ingredient	Dexrazoxane hydrochloride	Dexrazoxane hydrochloride
Primary use	Anthracycline extravasation	Anthracycline cardioprotection
Administration	Intravenous infusion	Intravenous infusion
Dosing pattern	Three-day regimen	Administered before selected anthracycline doses
Formulation	Sterile powder for reconstitution	Sterile powder for reconstitution
Commercial buyer	Oncology hospitals and infusion providers	Oncology hospitals and infusion providers
Key differentiation	Extravasation indication and emergency access	Cardioprotection indication and dosing workflow

The products share an active ingredient but are not interchangeable in clinical use. Totect’s commercial position depends on rapid access during an infrequent but urgent event. Cardioprotection products operate in a planned treatment workflow and may have different purchasing dynamics.

What licensing and partnering opportunities exist?

Licensing value is most likely in technology that improves preparation, storage, or distribution. Relevant partner categories include:

• Injectable formulation companies
• Contract development and manufacturing organizations
• Hospital-pharmacy device manufacturers
• Oncology supportive-care companies
• Specialty distributors
• Group purchasing organizations
• Emergency medication-kit suppliers

A licensee would likely prioritize a product with demonstrated room-temperature stability, low reconstitution time, a scalable sterile manufacturing process, and a clear FDA pathway. A formulation without measurable workflow or shelf-life improvement would face limited commercial leverage.

Key Takeaways

• Totect is a dexrazoxane hydrochloride intravenous product for anthracycline extravasation.
• Its current formulation strategy is a sterile powder for reconstitution rather than a complex excipient system.
• The strongest opportunities are ready-to-use liquid presentations, dual-chamber systems, improved lyophilization, and emergency treatment kits.
• Generic entry risk is material because the active ingredient and conventional injectable format are mature.
• Regulatory exclusivity from the 2007 approval has expired; current risk depends on any remaining listed or unlisted patents.
• Device, manufacturing, stability, and packaging claims may provide more defensible protection than broad excipient claims.
• Commercial differentiation depends on rapid preparation, reduced pharmacy workload, reliable emergency inventory, and reduced product waste.

FAQs

Can Totect be reformulated without changing the active ingredient?

Yes. Reformulation could change the excipient system, vial configuration, reconstitution method, container closure, or final dosage presentation. The regulatory pathway would depend on whether the reformulation remains pharmaceutically equivalent and whether the change affects safety, stability, or clinical performance.

Is a ready-to-use Totect formulation commercially attractive?

Yes, if it achieves adequate shelf life, sterility assurance, and chemical stability without imposing cold-chain costs. The main benefit would be faster administration and fewer pharmacy preparation steps.

Could a generic dexrazoxane product replace Totect?

A therapeutically and pharmaceutically equivalent dexrazoxane product could compete with Totect, subject to FDA approval, labeling, supply reliability, and hospital procurement requirements. Indication-specific labeling and product availability would affect substitution.

What excipient would most improve dexrazoxane injection?

No single excipient can be identified as commercially superior without stability and compatibility data. The highest-value formulation objective is a stable, low-particulate, rapidly prepared product with minimal handling.

Can a Totect competitor obtain patent protection?

Yes. Potential protection could cover a stabilized liquid formulation, a lyophilized composition, a dual-chamber container, a closed-system transfer device, a manufacturing process, or a defined in-use stability profile. Broad protection for dexrazoxane itself is unlikely to be available for a mature active ingredient.

References

1. U.S. Food and Drug Administration. (2007). Totect (dexrazoxane hydrochloride) for injection: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.